BlackRock Japan’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Japan’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-90,983	Closed	-$6.17M	–	1312
2016 Q3	$6.17M	Buy	90,983 +1,229	+1%	+$86.7K	0.02%	618
2016 Q2	$4.98M	Buy	89,754 +181	+0.2%	+$11.4K	0.02%	637
2016 Q1	$5.62M	Sell	89,573 -346	-0.4%	-$23K	0.02%	613
2015 Q4	$8.46M	Sell	89,919 -47	-0.1%	-$4.36K	0.03%	548
2015 Q3	$7.23M	Sell	89,966 -3,760	-4%	-$418K	0.03%	566
2015 Q2	$11.2M	Buy	+93,726	New	+$11.2M	0.04%	463
2014 Q3	–	Sell	-1,070	Closed	-$68K	–	1249
2014 Q2	$68K	Sell	1,070 -1,240	-54%	-$73.7K	﹤0.01%	997
2014 Q1	$155K	Buy	+2,310	New	+$179K	﹤0.01%	989

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Japan's ALNY Position: Q4 2016 in Review

BlackRock Japan sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 90,983 shares — an estimated $6.17M sold.

BlackRock Japan first reported a position in ALNY in Q1 2014 and held it in 8 quarters. The position peaked at $11.2M in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

BlackRock Japan reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
BlackRock Japan sold 90,983 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $6.17M.
BlackRock Japan first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 8 quarters.
BlackRock Japan's Alnylam Pharmaceuticals position peaked at $11.2M in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.